Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study-Reference-Cited by-同舟云学术

Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study

Published:2019-07-09 Issue:6 Volume:106 Page:1268-1279
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Suri Ajit¹,Mould Diane R.²,Song Gregory¹,Collins Graham P.³,Endres Christopher J.⁴,Gomez‐Navarro Jesús¹,Venkatakrishnan Karthik¹

Affiliation:

1. Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge Massachusetts USA

2. Projections Research, Inc. Phoenixville Pennsylvania USA

3. Oxford Cancer and Haematology CentreOxford University Hospital Oxford UK

4. Seattle Genetics, Inc. Bothell Washington USA

Funder

Seattle Genetics

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1530

Reference31 articles.

1. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review

2. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma

3. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions

4. Seattle Genetics.ADCETRIS®(brentuximab vedotin). [prescribing information]. (November2018). Accessed December 5 2018.

5. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates: A review of cutaneous adverse effects;Journal of the American Academy of Dermatology;2024-07

2. Time‐varying brentuximab vedotin pharmacokinetics and weight‐based dosing in paediatric patients despite lower exposure in those aged 2 to <6 and 6–11 years;British Journal of Clinical Pharmacology;2024-06-12

3. Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma;Clinical Cancer Research;2024-05-29

4. Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice;Cancers;2024-05-10

5. Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors;Clinical Pharmacokinetics;2024-04